Is Enclomiphene FDA Approved? | Elite Bio Supply

Is Enclomiphene FDA Approved?

Enclomiphene is not FDA approved. It came closest to approval under the brand name Androxal, developed by Repros Therapeutics. Androxal completed a full Phase III clinical development program, including two pivotal trials comparing it against topical testosterone replacement therapy in men with secondary hypogonadism. That is an unusual level of clinical development for a compound that ultimately did not receive regulatory approval, and it is worth understanding exactly why approval was not granted.

The FDA’s position was not that enclomiphene was ineffective or unsafe. The Phase III data clearly demonstrated that it worked. In Wiehle et al. (2014), a pivotal Phase III study, 77 percent of men achieved testosterone normalization on 25 mg per day of enclomiphene, comparable to the 81 percent normalization rate on topical testosterone therapy. The FDA’s concern was that any drug intended for chronic use in male hormone management required long-term cardiovascular outcomes data, similar to what was eventually required for testosterone therapies following the FDA’s class-wide safety review of testosterone products in 2015.

Repros Therapeutics did not conduct the cardiovascular outcomes study the FDA required. This was a business and resource decision, not a response to safety signals. The company later abandoned Androxal development entirely. The result is that enclomiphene has more human clinical trial data than many approved drugs, but sits outside the formal approval pathway due to an incomplete regulatory submission, not failed trials.

The Phase III Evidence Base for Enclomiphene

Understanding the clinical trial history puts the “not FDA approved” status in proper context. The development program for Androxal was rigorous by any standard.

Phase II work, including Kim et al. (2013, doi:https://pubmed.ncbi.nlm.nih.gov/26496621/), established dose-response relationships. Doses of 12.5 mg per day, 25 mg per day, and comparator conditions were studied. The 25 mg dose produced the most consistent testosterone normalization while maintaining a favorable tolerability profile. Importantly, Phase II confirmed that enclomiphene, unlike racemic clomiphene, did not cause significant mood-related side effects attributable to zuclomiphene accumulation.

The pivotal Phase III work, documented in Wiehle et al. (2014, Wiehle et al., 2014, doi:10.1111/andr.12150), enrolled men with secondary hypogonadism (morning testosterone below 300 ng/dL with low or inappropriately normal LH). Subjects were randomized to enclomiphene 12.5 mg, enclomiphene 25 mg, or topical testosterone gel. At 16 weeks, 77 percent of the enclomiphene 25 mg group achieved testosterone normalization. Crucially, this group also maintained sperm concentration and gonadotropin levels, while the testosterone gel group experienced significant reductions in both.

This is a meaningful clinical dataset. It represents the standard of evidence applied to drugs that actually reach pharmacy shelves. The difference between enclomiphene and approved testosterone therapies is not the quality of the evidence, it is the completion of the regulatory paperwork.

Enclomiphene in Canada and Research Use

In Canada, the FDA approval status of a compound does not determine its legal accessibility as a research compound. Health Canada regulates drug products sold for therapeutic use. Research compounds fall into a separate category: they are not pharmaceutical products, and their regulatory status is governed by whether they appear on controlled substance schedules, not whether they hold drug approval.

Enclomiphene is not listed on any Health Canada controlled substance schedule. It can be purchased from Canadian research compound suppliers including Elite Bio Supply. This makes it accessible for research without requiring a prescription or physician involvement, which would be required if it were an approved pharmaceutical drug dispensed through a pharmacy.

EMA and EU status is similar in logic but different in outcome. Clomiphene (racemic) is prescription-only across most EU member states as it holds approved indications. Enclomiphene, lacking any approved indication anywhere, would typically require a special import authorization in EU jurisdictions. Canadian regulatory treatment is more permissive toward unapproved research compounds.

Dosage Note

Phase III used 12.5 mg and 25 mg daily doses. Elite Bio Supply’s enclomiphene comes in 50 mg tablets (5-count pack). Research subjects typically halve the tablet to achieve 25 mg doses, or quarter it for 12.5 mg doses. A pill cutter is recommended for consistent splitting. At 25 mg per day, one 5-tablet pack covers a 10-day research window.

Frequently Asked Questions

If enclomiphene is not FDA approved, how do I know it is safe?

Safety is a separate question from approval status. FDA approval requires a complete regulatory package including manufacturing, labeling, long-term safety surveillance, and outcomes data. None of those requirements are about whether the drug is effective or acutely safe at typical doses. The Phase III trials for enclomiphene showed a tolerability profile similar to placebo, with the most common adverse events being hot flushes in a minority of subjects and no serious adverse events attributable to the compound. The safety dataset is solid. What is missing is the long-term cardiovascular outcomes dataset the FDA required for a new chronic hormone therapy indication.

Will enclomiphene ever receive FDA approval?

Repros Therapeutics, the original developer, no longer exists as an independent company following its merger with Strongbridge Biopharma and subsequent corporate changes. No other company has taken on the Androxal NDA (New Drug Application). A new developer could theoretically file a 505(b)(2) application using the existing Phase III data plus new cardiovascular outcomes data, but this would require significant investment. As of 2026, no such program is publicly known to be underway.

Is enclomiphene the same compound as what was in the Androxal trials?

Yes. Androxal was the brand name for trans-clomiphene citrate, which is enclomiphene. The compound itself is not proprietary: the molecule is off-patent. Research compound suppliers including Elite Bio Supply source pharmaceutical-grade enclomiphene citrate manufactured to the same chemical specification as what was used in the clinical trials. Identity and purity are confirmed by third-party COA testing.

Sourcing Enclomiphene in Canada

Elite Bio Supply offers pharmaceutical-grade enclomiphene citrate with third-party purity verification. Our product matches the chemical specification used in Phase II and Phase III clinical trials. Domestic Canadian shipping via Canada Post means no customs exposure. Cryptocurrency payment accepted. Each batch comes with a certificate of analysis confirming identity, purity, and concentration.

Related Guides

• Enclomiphene Dosage Guide
• Enclomiphene for Secondary Hypogonadism
• Is Enclomiphene Legal in Canada?
• Clomid vs Enclomiphene: A Comparison